whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients

November 2008

Experts are debating whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients.

The lay press picked up on a recent meta-analysis linking tiotropium (Spiriva) and ipratropium (Atrovent, Combivent) to a higher risk of cardiovascular events.

But don't jump to conclusions. There are two sides to the story.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote